RxDoctor Payments DataLook up a doctor →

Corinne Young

Family · Colorado Springs, CONPI 1578581021

Payments from drug & device makers

$272,065in general payments, 2019–2025

Across 1,077 payments — averaging $252.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Regeneron Healthcare Solutions, Inc.$111K
  • Sanofi$80K
  • AstraZeneca$20K
  • GSK$20K
  • Grifols USA, LLC$11K
  • Boehringer Ingelheim$7K
  • plus $23K from 47 others

What the payments were for

  • Consulting fees$68,95925%
  • Speaking & faculty fees$135,21450%
  • Travel & lodging$45,47417%
  • Food & beverage$22,0758%
  • Education$3440%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$272,065 in reported general payments places this provider in the 95th percentile of 2,182 family providers in Colorado.

See all family providers in Colorado

Medicare billing

Part B allowed, 2024
$58,091
Medicare patients
376
Services billed
666

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter293$293,017
AdempasRiociguat12$169,052
OfevNintedanib Esylate12$152,839
Breztri AerosphereBudesonide/Glycopyr/Formoterol122$104,960
Spiriva RespimatTiotropium Bromide116$97,432
Stiolto RespimatTiotropium Br/Olodaterol Hcl90$55,247
NucalaMepolizumab14$52,473
Breo ElliptaFluticasone/Vilanterol63$39,052
Spiriva HandihalerTiotropium Bromide52$38,976
SymbicortBudesonide/Formoterol Fumarate77$27,666
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr23$23,821
Incruse ElliptaUmeclidinium Bromide40$21,366
Fluticasone-SalmeterolFluticasone Propion/Salmeterol106$15,450
Albuterol Sulfate HfaAlbuterol Sulfate300$10,783
Tiotropium Bromide17$4,869

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Nucala, Breo Ellipta, Anoro Ellipta, Incruse Ellipta$19,760$429,730433 claims
Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat$7,484$305,519218 claims
BayerAdempas$398$169,05212 claims
AstraZenecaBreztri Aerosphere, Symbicort$20,257$132,627199 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,182 family providers in Colorado.

Other family in Colorado Springs

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →